Considering that the forced expression of CTLA-4 on Tregs in the context of RA can rejuvenate their inhibitory function, and conversely, the blockade of CTLA-4 on healthy Tregs can impair their functionality, researchers theorize that CTLA-4 present on RA Tregs could be a prospective therapeutic target for direct manipulation within these cells. The gene discussed is CTLA4; the disease is rheumatoid arthritis.